Subtype
Pancreatobiliary Carcinoma
CI-CAN-00001365Explore in graph →
698 active trials8 approved drugs60 evidence items
- NCIt
- C166418
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001365Explore in graph →
Clinical trials
2,128 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (303)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06018883 | Vitamin C to Chemotherapy Related Anemia in Pancreatic Cancer(PTCA199-3) | unknown | Phase 3 | 100 | Fudan UniversityOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT06440018 | INSPIRE: a Multi-Cancer Early Detection Study(INSPIRE) | unknown | — | 5,350 | Singlera Genomics Inc.INDUSTRY | 1 | Feb 21, 2025 | clinicaltrials |
| NCT05215665 | GEMOX Combined With Targeted Therapy and Immunotherapy for Patients With Advanced Cholangiocarcinoma | unknown | N/A | 146 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 11, 2024 | clinicaltrials |
| NCT05042128 | The ASCEND Study: Gemcitabine and Nab-Paclitaxel With LSTA1 (Certepetide) or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma(ASCEND) | unknown | Phase 2 | 158 | Australasian Gastro-Intestinal Trials GroupNETWORK | 2 | Oct 22, 2024 | clinicaltrials |
| NCT04913337 | Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies | unknown | Phase 1 / Phase 2 | 179 | NGM Biopharmaceuticals, IncINDUSTRY | 3 | Oct 2, 2024 | clinicaltrials |
| NCT06006390 | CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 60 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Aug 9, 2024 | clinicaltrials |
| NCT06505486 | GEMOX-HAIC Plus GEM-SYS in Combination With Lenvatinib and PD-1 Inhibitor for Large Unresectable ICC | unknown | — | 21 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jul 17, 2024 | clinicaltrials |
| NCT06497777 | The Application of DNA Nanomachines for Detecting microRNA in Blood for the Diagnosis of Pancreatic Cancer. Diagnosis of Pancreatic Cancer | unknown | — | 30 | National Taiwan University HospitalOTHER | 1 | Jul 12, 2024 | clinicaltrials |
| NCT06467565 | NALIRIFOX as Induction Therapy in LAPC | unknown | Phase 2 | 20 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jun 21, 2024 | clinicaltrials |
| NCT06417606 | Lenvatinib and Adebrelimab Combined With GEMOX in the Perioperative Treatment of Potentially Resectable Intrahepatic Cholangiocarcinoma | unknown | Phase 4 | 20 | Zhiyong HuangOTHER | 1 | May 22, 2024 | clinicaltrials |
| NCT03337087 | Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer | unknown | Phase 1 / Phase 2 | 18 | Academic and Community Cancer Research UnitedOTHER | 1 | May 17, 2024 | clinicaltrials |
| NCT06036563 | Prospective Screening and Differentiating Common Cancers Using Peripheral Blood Cell-Free DNA Sequencing | unknown | — | 3,200 | Air Force Military Medical University, ChinaOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT06212700 | PRIORITY-CONNECT 2 Pilot Trial | unknown | N/A | 20 | Surgical Outcomes Research Centre (SOuRCe)NETWORK | 1 | Apr 25, 2024 | clinicaltrials |
| NCT04143152 | Pancreatic Cancer Biomarker Study | unknown | — | 300 | Van Andel Research InstituteOTHER | 1 | Apr 23, 2024 | clinicaltrials |
| NCT06375642 | A Single Arm, Single Centered Phase II Trial on the Combination of Adebrelimab, Surufatinib and Irinotecan Liposome-based HAIC in Advanced iCC | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT04104230 | Quebec Pancreas Cancer Study(QPCS) | unknown | — | 2,000 | George ZogopoulosOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT06369480 | Prognostic Factors for Survival in Patients With Cholangiocarcinoma | unknown | — | 2,000 | Rigshospitalet, DenmarkOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT06363123 | Plasma Metabolic Biomarkers for Multi-Cancer Diagnosis | unknown | — | 2,700 | Beijing Friendship HospitalOTHER | 1 | Apr 15, 2024 | clinicaltrials |
| NCT05519605 | Bile Duct Drainage After ERCP Failure: EUS-BD vs PTBD(BESTDRAIN) | unknown | — | 61 | Radboud University Medical CenterOTHER | 1 | Apr 11, 2024 | clinicaltrials |
| NCT05311618 | Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors | unknown | Phase 1 | 71 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | Apr 1, 2024 | clinicaltrials |
| NCT06335927 | HAIC Combined With Cadonilimab and Regorafenib as 2nd-line Treatment for ICC | unknown | Phase 2 | 45 | Fudan UniversityOTHER | 1 | Mar 28, 2024 | clinicaltrials |
| NCT05048524 | Peri-operative SLOG for Localized Pancreatic Cancer | unknown | Phase 2 | 64 | National Health Research Institutes, TaiwanOTHER | 1 | Mar 27, 2024 | clinicaltrials |
| NCT05170802 | Pancreatic Cancer & Surgical Resection | unknown | — | 30 | Methodist Health SystemOTHER | 1 | Mar 27, 2024 | clinicaltrials |
| NCT06304766 | Open Versus Laparoscopic Ablation of Liver Malignancies(OPTIMAL) | unknown | N/A | 80 | Rigshospitalet, DenmarkOTHER | 1 | Mar 13, 2024 | clinicaltrials |
| NCT04024358 | A New Scoring System for Perineural and Vascular Invasion in Pancreatic Cancer(VANISSh) | unknown | — | 500 | Massimo FalconiOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT05872867 | Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (MK-3475-E90/KEYNOTE-E90) | unknown | Phase 1 | 54 | Wellmarker BioINDUSTRY | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06302881 | Differentiating Tumor-stroma Ratio in Pancreatic Ductal Adenocarcinoma | unknown | — | 207 | First Affiliated Hospital of Chongqing Medical UniversityOTHER | 0 | Mar 12, 2024 | clinicaltrials |
| NCT05124002 | Recombinant Human Adenovirus Type 5 Plus HAIC of FOLFOX for Intrahepatic Cholangiocarcinoma | unknown | Phase 4 | 66 | Beijing Tsinghua Chang Gung HospitalOTHER | 1 | Mar 4, 2024 | clinicaltrials |
| NCT06291779 | Diagnosis of Pancreatic Cancer by Purine Metabolite (Hypoxanthine, Xanthine) in Urine | unknown | — | 120 | Ho-Seong HanOTHER | 1 | Mar 4, 2024 | clinicaltrials |
| NCT03924466 | Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients(VUBAR) | unknown | Phase 2 | 55 | Universitair Ziekenhuis BrusselOTHER | 1 | Feb 16, 2024 | clinicaltrials |
| NCT04246710 | Pancreatic Cancer Molecular Sub-classification Using Endoscopic Ultrasound Tissue Core Biopsy Samples | unknown | — | 160 | Catholic University of the Sacred HeartOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT05248750 | Genetic, Microenvironmental, and Immunological Factors in Unresectable Pancreatic Ductal Adenocarcinoma | unknown | — | 250 | Catholic University of the Sacred HeartOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT04149691 | Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies | unknown | Phase 1 | 42 | Celon Pharma SAINDUSTRY | 1 | Feb 7, 2024 | clinicaltrials |
| NCT06214533 | Celiac plExus Block to Reduce OpioID Consumption Following Hepato-pancreato-biliary Mini-invasive Surgery(CEBOIDS) | unknown | N/A | 60 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 0 | Jan 19, 2024 | clinicaltrials |
| NCT06208436 | The Survival Outcome of Adjuvant Chemotherapy for Stage I Pancreatic Cancer | unknown | — | 250 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 17, 2024 | clinicaltrials |
| NCT04883450 | PRedictiOn Algorithms for the DeTECTion of Early Stage Pancreatic Cancer(PRO-TECT) | unknown | — | 126 | Kaiser PermanenteOTHER | 1 | Jan 16, 2024 | clinicaltrials |
| NCT06206382 | Surgical Results of Resection of Locally Advanced Pancreatic Cancer | unknown | — | 80 | Assiut UniversityOTHER | 0 | Jan 16, 2024 | clinicaltrials |
| NCT05955157 | Combined S-1 With DC+CIK As Maintenance Therapy For Advanced Pancreatic Ductal Adenocarcinoma | unknown | Phase 2 / Phase 3 | 52 | University of MalayaOTHER | 1 | Jan 10, 2024 | clinicaltrials |
| NCT06192784 | Combined DEB-TACE, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma(CCGLC-012) | unknown | Phase 2 | 36 | Tongji HospitalOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT06194695 | DEB-TACE, Lenvatinib and Anti-PD(L)1 Antibody as Conversion Therapy for Intrahepatic Cholangiocarcinoma(CCGLC-009) | unknown | — | 100 | Ze-yang Ding, MDOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT02611453 | Cholangiography Using Carbon Dioxide Versus Iodinated Contrast in ERCP | unknown | N/A | 40 | University of VirginiaOTHER | 1 | Jan 3, 2024 | clinicaltrials |
| NCT04324294 | Contrast Enhanced Endoscopic Ultrasound in Pancreas Lesions | unknown | Phase 1 | 200 | Cedars-Sinai Medical CenterOTHER | 1 | Dec 20, 2023 | clinicaltrials |
| NCT05845554 | Application of Chromosomal Instability in Early Diagnosis of Biliary Tract Carcinoma | unknown | — | 300 | Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical UniversityOTHER | 1 | Dec 18, 2023 | clinicaltrials |
| NCT06172634 | A Single-center Clinical Study to Evaluate the Safety and Efficacy of Autologous Bone Marrow-derived DCs(CellgramDC-WT1) and Immune Checkpoint Inhibitors in Patients With Metastatic Pancreatic Cancer Who Have Failed First-line or More Standard Chemotherapy(DICI_PC) | unknown | Phase 1 / Phase 2 | 10 | Soonchunhyang University HospitalOTHER | 0 | Dec 15, 2023 | clinicaltrials |
| NCT04850430 | Gastric Venous Reconstruction After Total Pancreatectomy(GENDER) | unknown | N/A | 20 | University Hospital HeidelbergOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT06168552 | Fluorescent Navigation Technology in Radical Resection of Pancreatic Cancer(CISPD-6) | unknown | Phase 1 / Phase 2 | 20 | Zhejiang UniversityOTHER | 0 | Dec 13, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Aug 7, 2025source: clinicaltrials